approach to antiplatelet and anticoagulant therapy before endoscopic procedures
نویسندگان
چکیده
the use of anticoagulant and antiplatelet agents has become more prevalent during the past decades. these drugs may potentially cause gastrointestinal (gi) bleeding. thus, there is an increasing need for gi endoscopy in patients who take these medications. in patients who take anticoagulant and antiplatelet agents, the appropriate conditions under which endoscopic procedures should be performed remain unclear. in this manuscript, we reviewed studies regarding this context in an attempt to present a practical guideline for management these patients.
منابع مشابه
Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures.
1.1 Acute gastro-intestinal haemorrhage Acute gastro-intestinal haemorrhage in patients on anticoagulant or antiplatelet agents is a high-risk situation. The immediate risk to the patient from haemorrhage may outweigh the risk of thrombosis as a result of stopping anticoagulant or antiplatelet therapy. Patients need to be assessed on an individual basis, and it is not possible to give unequivoc...
متن کاملManaging anticoagulation and antiplatelet therapy before interventional radiology procedures.
Before any interventional radiology procedure, including biopsy and abscess drainage, patients should have testing to determine the complete blood count (including platelet count), activated partial thromboplastin time and international normalized ratio. The tests should be done as close to the time of the procedure as possible. For stable patients, the timing of blood tests should be within on...
متن کاملEndoscopic procedures in patients under clopidogrel/dual antiplatelet therapy: to do or not to do?
BACKGROUND Dual antiplatelet therapy has to be used for at least one month after placement of bare metal coronary stents and for a minimum of one year after placement of drug eluting stents. Because of the higher risk of bleeding, guidelines recommend cessation of clopidogrel seven days prior to high-risk endoscopic procedures and to delay elective surgery/endoscopy until dual antiplatelet ther...
متن کاملManagement of anticoagulant and antiplatelet therapy in patients undergoing interventional pulmonary procedures.
There has been great progress in antithrombotic therapy over the past several years. Its use has increased with the advent of novel anticoagulants, as these medications do not require frequent blood tests for monitoring. Antithrombotic therapy is aimed at reducing the risk of thromboembolic events in patients with atrial fibrillation, coronary artery disease, deep vein thrombosis, valvular hear...
متن کاملAnticoagulant and antiplatelet medications.
CRITICALCARENURSE Vol 26, No. 3, JUNE 2006 19 2. Paradiso-Hardy FL, Madan M, Radhakrishnan S, Hurden S, Cohen EA. Severe thrombocytopenia possibly related to readministration of eptifibatide. Catheter Cardiovasc Interv. September 2001;54:63-67. 3. Hongo RH, Brent BN. Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol. 2001;88:428-431. 4. Yoder M, Edwards RF. Reversibl...
متن کاملBiliary-Pancreatic Endoscopic and Surgical Procedures in Patients under Dual Antiplatelet Therapy: A Single-Center Study
BACKGROUND/AIMS Dual antiplatelet therapy has to be used for at least 1 month after placement of bare metal coronary stents and for a minimum of 1 year after placement of drug eluting stents. Because of the higher risk of bleeding, guidelines strongly recommend to delay elective surgery until dual antiplatelet therapy is ended. However, no data are available regarding the bleeding risk in patie...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
گوارشجلد ۱۶، شماره ۴، صفحات ۲۲۸-۰
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023